Psoriatic arthritis screening tools: study design and methodologic challenges - reply from authors
Abstract
Funding sources: None. Conflicts of interest: None declared. Dear Editor, We thank Dr Qureshi et al. (‘Psoriatic arthritis screening tools: study design and methodologic challenges’)1 for their comments about our study [‘Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study)’].2 The CONTEST study was carried out in dermatology clinics only. As they point out, there would be little point in administering these instruments in rheumatology clinics. The low response rate is disappointing, but reflects the likely response to the use of such tools in clinical practice. We would indicate that our sample size was almost fully achieved so the study had sufficient power to compare the three instruments. Unless Dr Qureshi et al. feel that the Psoriatic Arthritis Screening and Evaluation tool was specifically disadvantaged by the nonresponders, we can't see why the study failed to be a fair comparison of the three tools administered in the setting for which they were designed to work.
Related Papers
- → Prevalence of Psoriasis and Psoriatic Arthritis and Patient Perceptions of Severity in Sweden, Norway and Denmark: Results from the Nordic Patient Survey of Psoriasis and Psoriatic Arthritis(2018)33 cited
- → Cardiovascular Comorbidities of Psoriasis and Psoriatic Arthritis: A Report from the GRAPPA 2012 Annual Meeting(2013)25 cited
- → Risk factors and predictors of psoriatic arthritis in patients with psoriasis(2013)11 cited
- → Biomarkers for Comorbidities in Psoriasis: A Report from the Grappa 2011 Annual Meeting(2012)1 cited
- → Influence of age of onset of psoriasis on prevalence and clinical characteristics of psoriatic arthritis (according to the registry of patients with psoriasis)(2022)